A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Sponsor

National Cancer Institute, Naples (Other)

Overall Status

Recruiting

CT.gov ID

NCT03975114

Collaborator

University of Campania "Luigi Vanvitelli" (Other), AstraZeneca (Industry)

460

Enrollment

Location

Arms

54.3

Anticipated Duration (Months)

8.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a randomized phase 2 trial aiming to assess the early efficacy of two experimental treatment sequences.

Three arms are planned; (i) standard chemotherapy followed at progression by single agent immunotherapy with durvalumab (CT), (ii) experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy, (iii) experimental combination immunotherapy with durvalumab+tremelimumab followed at progression by chemotherapy.

The the two experimental strategies will be compared with the standard strategy in terms of 12-month overall survival, time considered informative for the type of treatment and disease

Condition or Disease	Intervention/Treatment	Phase
Carcinoma, Non-Small-Cell Lung	Drug: Chemotherapy Drug: Durvalumab Drug: Tremelimumab	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

460 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Comparative Randomized Phase 2 DesignComparative Randomized Phase 2 Design

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Actual Study Start Date :

Dec 20, 2018

Anticipated Primary Completion Date :

Dec 31, 2022

Anticipated Study Completion Date :

Jun 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Chemo first Standard chemotherapy followed at progression by durvalumab	Drug: Chemotherapy Any approved first line chemotherapy regimen at Investigators' choice Drug: Durvalumab Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
Experimental: Immuno Monotherapy first Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy	Drug: Chemotherapy Any approved first line chemotherapy regimen at Investigators' choice Drug: Durvalumab Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
Experimental: Immuno Combination Therapy first experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy	Drug: Chemotherapy Any approved first line chemotherapy regimen at Investigators' choice Drug: Durvalumab Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal Drug: Tremelimumab Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)

Arm

Intervention/Treatment

Active Comparator: Chemo first

Standard chemotherapy followed at progression by durvalumab

Drug: Chemotherapy

Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab

Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Experimental: Immuno Monotherapy first

Experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy

Drug: Chemotherapy

Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab

Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Experimental: Immuno Combination Therapy first

experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy

Drug: Chemotherapy

Any approved first line chemotherapy regimen at Investigators' choice

Drug: Durvalumab

Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal

Drug: Tremelimumab

Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)

Outcome Measures

Primary Outcome Measures

12-month overall survival [12 months]
12-month overall survival is defined as the Kaplan-Meier (K-M) survival probability at 12 months after randomization (Chen 2015).

Eligibility Criteria

Criteria

Ages Eligible for Study:

70 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female >= 70 years of age.
Histological documentation of primary squamous or non squamous non-small cell lung carcinoma.
Availability of archived tumor tissue block or newly cut unstained slides for PD-L1 determination.
Stage IV or IIIB disease with supraclavear metastatic nodes (according to TNM 7th edition).
Clinical or radiologic evidence of disease (at least one measurable or non measurable lesion).
ECOG performance status 0 to 1.
Life expectancy > 3 months.
Adequate renal and hepatic function, defined as:
Total serum bilirubin ≤ 1.5 institutional ULN.
AST and/or ALT ≤ 2.5 x ULN for the institution (or ≤ 5 x ULN if liver metastases are present)
Serum creatinine ≤ 1.5 x ULN for the institution (or calculated creatinine clearance ≥ 40 mL/min/1.73 m2).
Adequate bone marrow function, defined as:
Haemoglobin <= 9.0 g/dL
Absolute neutrophils count (ANC) >= 1.5 x 109/L (> 1500 per mm3)
Platelet count <= 100 x 109/L(>100,000 per mm3).
Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.

Exclusion Criteria:

Cancer related

Activating epidermal growth factor receptor mutation (exon19 deletion or exon 21 L858R mutation or other activating/sensitizing mutations).
ALK or ROS1 positive (immunohistochemistry or FISH)
Mixed small-cell lung cancer and NSCLC histology.

Prior, current or planned treatment related

Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if > 6 months previously).
Prior exposure to immunomodulatory therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies.
Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment (intranasal and inhaled corticosteroids at physiological doses not exceeding 10 mg/day of prednisone or an equivalent corticosteroid are allowed).
Any concurrent investigational product or other anticancer treatment.

Prior or concomitant conditions or procedures related

Active or prior documented autoimmune disease within the past 2 years (subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years, are not excluded).
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
History of allogeneic organ transplant
History of active primary immunodeficiency.
Active infection, including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
Receipt of live attenuated vaccine within 30 days prior to the first dose of study drugs.
Patients with previous malignancies (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA) are excluded only if the histological diagnosis of the current disease does not definitely support the pulmonary origin.
Brain metastases or spinal cord compression, unless asymptomatic, previously treated, and stable off steroids and anti-convulsants for at least one month prior to study entry.
Leptomeningeal carcinomatosis
Clinically significant cardiovascular disease, including:
Myocardial infarction or unstable angina pectoris within < 6 months prior to the first study treatment
New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF)
Uncontrolled hypertension
Serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia)
Peripheral vascular disease > grade 3 (i.e. symptomatic and interfering with activities of daily living requiring repair or revision)
Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction.
Serious active infection requiring i.v. antibiotics at enrollment.
Known hypersensitivity to any of the study drugs or excipients.
Evidence of any other concomitant pathologies, physical examination or laboratory findings (including but not limited to active peptic ulcer disease or gastritis, active bleeding diatheses or psychiatric illness) or social situation that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications.
Radiotherapy treatment to the chest or to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study treatment (patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy are also excluded).
Major surgical procedure within 28 days prior to the first dose of study drugs.
Male patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of study treatment.